Literature DB >> 33991580

Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in PEG allergic patients.

Alexander Troelnikov1, Griffith Perkins2, Chino Yuson3, Aida Ahamdie4, Summaya Balouch5, Pravin Hissaria6.   

Abstract

BACKGROUND: The mechanisms underpinning allergic reactions to the BNT162b2 (Pfizer) COVID-19 vaccine remain unknown, with polyethylene glycol (PEG) contained in the lipid nanoparticle suspected as being the cause.
OBJECTIVE: To evaluate the performance of skin testing and basophil activation testing to PEG, polysorbate 80, BNT162b2 and AZD1222 (Astra-Zeneca) COVID-19 vaccines in patients with a history of PEG allergy.
METHODS: Three known PEG allergic participants and three healthy controls were recruited, and evaluated for hypersensitivity to the BNT162b2 and AZD1222 vaccines and related compounds by skin testing and basophil activation measured by CD63 upregulation using flow cytometry.
RESULTS: We found that the BNT162b2 vaccine induced positive skin tests in PEG allergic patients, whereas traditional PEG skin testing was negative in two of three patients. One patient was found to be co-sensitized to both the BNT162b2 and AZD1222 vaccines due to cross-reactive PEG and polysorbate allergy. The BNT162b2 vaccine, but not PEG alone, induced dose-dependent activation of all patients' basophils ex vivo. Similar basophil activation could be induced by PEGylated liposomal doxorubicin, suggesting that PEGlyated lipids within nanoparticles, and not PEG in its native state, are able to efficiently induce degranulation.
CONCLUSIONS: Our findings implicate PEG, as covalently modified within the vaccine lipid nanoparticle, as a potential trigger of anaphylaxis to BNT162b2.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID: 33991580     DOI: 10.1016/j.jaci.2021.04.032

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  26 in total

Review 1.  Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges.

Authors:  Ramesh Kandimalla; Pratik Chakraborty; Jayalakshmi Vallamkondu; Anupama Chaudhary; Sonalinandini Samanta; P Hemachandra Reddy; Vincenzo De Feo; Saikat Dewanjee
Journal:  Biomedicines       Date:  2021-11-22

2.  Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines.

Authors:  Mariko Mouri; Mitsuru Imamura; Shotaro Suzuki; Tatsuya Kawasaki; Yoshiki Ishizaki; Keiichi Sakurai; Hiroko Nagafuchi; Norihiro Matsumura; Marina Uchida; Takayasu Ando; Kohei Yoshioka; Seido Ooka; Takahiko Sugihara; Hiroshi Miyoshi; Masaaki Mori; Tomoyuki Okada; Masao Yamaguchi; Hiroyuki Kunishima; Motohiro Kato; Kimito Kawahata
Journal:  Allergol Int       Date:  2022-06-06       Impact factor: 7.478

3.  COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication.

Authors:  Tiago Azenha Rama; Joana Miranda; Diana Silva; Luís Amaral; Eunice Castro; Alice Coimbra; André Moreira; José Luís Plácido
Journal:  Vaccines (Basel)       Date:  2022-05-04

4.  Nanoparticle Surface Engineering with Heparosan Polysaccharide Reduces Serum Protein Adsorption and Enhances Cellular Uptake.

Authors:  Wen Yang; Lin Wang; Mulin Fang; Vinit Sheth; Yushan Zhang; Alyssa M Holden; Nathan D Donahue; Dixy E Green; Alex N Frickenstein; Evan M Mettenbrink; Tyler A Schwemley; Emmy R Francek; Majood Haddad; Md Nazir Hossen; Shirsha Mukherjee; Si Wu; Paul L DeAngelis; Stefan Wilhelm
Journal:  Nano Lett       Date:  2022-02-15       Impact factor: 12.262

Review 5.  COVID-19 vaccine development: milestones, lessons and prospects.

Authors:  Maochen Li; Han Wang; Lili Tian; Zehan Pang; Qingkun Yang; Tianqi Huang; Junfen Fan; Lihua Song; Yigang Tong; Huahao Fan
Journal:  Signal Transduct Target Ther       Date:  2022-05-03

6.  Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.

Authors:  Catherine Mark; Sumit Gupta; Angela Punnett; Julia Upton; Julia Orkin; Adelle Atkinson; Lindsay Clarke; Alice Heisey; Christine McGovern; Sarah Alexander
Journal:  Pediatr Blood Cancer       Date:  2021-08-16       Impact factor: 3.838

Review 7.  Do basophil activation tests help elucidate allergic reactions to the ingredients in COVID-19 vaccines?

Authors:  Bernadette Eberlein; Sonja Mathes; Jörg Fischer; Ulf Darsow; Tilo Biedermann; Knut Brockow
Journal:  Allergy       Date:  2022-03-25       Impact factor: 14.710

Review 8.  Cutaneous and hypersensitivity reactions associated with COVID-19 vaccination-a narrative review.

Authors:  Uwe Wollina; Anca Chiriac; Hristina Kocic; André Koch; Piotr Brzezinski
Journal:  Wien Med Wochenschr       Date:  2021-08-23

9.  COVID-19 vaccines and vaccine hesitancy: Role of the allergist/immunologist in promotion of vaccine acceptance.

Authors:  Joseph A Bellanti
Journal:  Allergy Asthma Proc       Date:  2021-08-09       Impact factor: 2.587

Review 10.  Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.

Authors:  Ana Sara Cordeiro; Yogita Patil-Sen; Maitreyi Shivkumar; Ronak Patel; Abdulwahhab Khedr; Mohamed A Elsawy
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.